Preview

Нефрология

Расширенный поиск
Доступ открыт Открытый доступ  Доступ закрыт Только для подписчиков

Дигидропиридиновые блокаторы кальциевых каналов для нефропротективной терапии гипертензивных больных с хронической болезнью почек

https://doi.org/10.36485/1561-6274-2021-25-2-27-34

Полный текст:

Аннотация

Амлодипин и селективные дигидропиридиновые блокаторы L-Са2+-каналов второго поколения при добавлении к ингибиторам АПФ или заменяющим их антагонистам АТ1-ангиотензиновых рецепторов не улучшают клинические почечные исходы у гипертензивных больных с хронической болезнью почек. Эти препараты не устраняют внутриклубочковую гипертензию, лежащую в основе гипертонической нефропатии, и могут оказывать неблагоприятное влияние на нейрогормональный статус организма, вызывая активацию симпатической и ренин-ангиотензин-альдостероновой систем. В обзоре представлены результаты клинических исследований, посвященных оценке эффективности применения в этой популяции пациентов нового дигидропиридинового блокатора L-Са2+-каналов третьего поколения лерканидипина, двойного блокатора T/L-Са2+-каналов бенедипина и двойного блокатора N/L-Са2+-каналов цилнидипина, отличающихся от своих предшественников выраженными нефропротективными свойствами.

Об авторах

О. Б. Кузьмин
Кафедра фармакологии Оренбургского государственного медицинского университета
Россия

Проф. Кузьмин Олег Борисович, д-р мед. наук

460000, Россия, г. Оренбург, Парковый пр., д. 7

Тел.: (8) 9198487679



В. В. Жежа
Кафедра фармакологии Оренбургского государственного медицинского университета
Россия

Жежа Владислав Викторович, канд. мед. наук

460000, Россия, г. Оренбург, Парковый пр., д. 7

Тел.: (8) 9510385128



В. В. Белянин
Кафедра фармакологии Оренбургского государственного медицинского университета
Россия

Белянин Виталий Васильевич канд мед наук

46000, Россия, Оренбург, Парковый пр., д. 7

Тел.: (8) 9878703415



Список литературы

1. Моисеев ВС, Мухин НА, Смирнов ВА и др. Национальные рекомендации. Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардио-нефропротекции. Клиническая фармакология и терапия 2014; 23 (3): 4-27

2. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31 (7):1281-1357. doi: 10.1097/01.hjh.0000431740.32696.cc

3. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease. Drugs 2019; 79 (4): 365-379. doi: 10.1007/s40265-019-1064-1

4. Xie X, Liu Y, Perkovic V et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis 2016; 67 (5): 728-741. doi: 10.1053/j.ajkd.2015.10.011

5. Cheng Y, Huang R, Kim S et al. Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2016; 95 (28): e4167. doi: 10.1097/MD.0000000000004167

6. Lu Z, Chen Y, Li L et al. Combination therapy of reninangiotensin system inhibitors plus calcium channel blockers versus other two-drug combinations for hypertension: a systematic review and meta-analysis. J Hum Hypertens 2017; 31 (1): 1-13. doi: 10.1038/jhh.2015.125

7. Risoz CV, Elisaf MS. Antihypertensive drugs and glucose metabolism. World J Cardiol 2014; 6 (7):517-530. doi: 10.4330/wic.v.6i.7.517

8. Grosskopf I, Shaish A, Charach J et al. Nifedipine treatment of hypertension is associated with accelerated clearance of postprandial lipemia. Horm Metab Res 2016; 48 (4): 257-262. doi: 10.1055/s-0035-1565180

9. Huang RS, Cheng YM, Zeng XX et al. Renoprotective effect of the combination of renin-angiotensin system inhibitor and calcium channel blocker in patients with hypertension and chronic kidney disease. Clin Med J (Engl.) 2016; 129 (5): 562-569. doi: 10.4103/0366-6999.176987

10. Rahman M, Pressel S, Davis BR et al. Renal outcomes in high-risk hypertensive patients with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005; 165 (8): 936-946. doi: 10.1001/archinte.165.8.936

11. Rahman M, Ford CE, Cutler JA et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012; 7 (6): 989-1002. doi: 10.2215/CJN.07800811

12. Esnault VL, Brown EA, Apetrei E et al. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3 year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther 2008; 30 (3): 482-489. doi: 10.1016/j.clinthera.2008.03.006

13. Narumi H, Takano H, Shindo S et al. Effects of valsartan and amlodipine on cardiorenal protection in Japanese hypertensive patients: the Valsartan Amlodipine Randomized Trial. Hypertens Res 2011; 34 (1): 62-69. doi: 10.1038/hr.2010.186

14. Backris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375 (9721): 1173-1181. doi: 10.1016/S0140-6736(09)62100-0

15. Takenaka T, Uchida K, Kojima E et al. Amlodipine and loop diuretics as a second anti-hypertensive medication for the treatment of hypertension with chronic kidney disease. Clin Exp Hypertens 2011; 33 (4): 210-215. doi: 10.3109/10641963.2011.583965

16. Hayashi K, Wakino S, Sugano N et al. Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100 (3): 342-353. doi: 10.1161/01.RES.0000256155.31133.49

17. Ott C, Schneider MP, Ralf U et al. Effects of manidipine vs amlodipine on intrarenal haemodynamics in patients with arte rial hypertension. J Clin Pharmacol 2013; 75 (1): 129-135. doi: 10.1111/j.1365-2125.2012.04336.x

18. Homma K, Hayashi K, Yamaguchi S et al.. Renal microcirculation and calcium channel subtypes. Curr Hypertens Rev 2013; 9 (3): 182-186. doi: 10.2174/1573402110666140131100617

19. Konoshita T, Makino Y, Kimura T et al. A new generation N/L-type calcium channel blocker leads to less activation of the renin-angiotensin system compared with conventional L-type calcium channel blocker. J Hypertens 2010; 28 (10): 2156-2160. doi: 10.1097/HJH.06013e32833d01dd

20. Tawaramoto K, Kaneto H, Hashiramoto M et al. Azelnidipine, but not amlodipine, reduces urinary albumin excretion and carotid atherosclerosis in subjects with type 2 diabetes: blood pressure control with olmesartan and azelnidipine in Type 2 diabetes (BOAT2 study). Diabetol Metab Syndr 2015; 17 (7) 80. doi: 10.1186/s13098-015-0073-9

21. Friis UG, Jorgensen F, Adreasen D et al. Membrane potential and cation channels in rat juxtaglomerular cells. Acta Physiol Scand 2004; 181 (4): 391-396. doi: 10.1111/j.1365-201X.2004.01310.x

22. Aritomi S, Konda T, Yoshimura M. L/N-type calcium channel blocker suppresses reflex aldosterone production induced by antihypertensive action. Heart Vessels 2012; 27 (4): 419-423. doi: 10.1007/s00380-011-0191-8

23. Verbeke F, Lindley E, Van Bortel L et al. European Renal Best Practice (EBP) position statement on the kidney disease: Improving Global Outcomes (KDIGO) clinical practice guideline for the management of blood pressure in nondialysis-dependent chronic kidney disease: an endorsement with caveats for real-life application. Nephrol Dial Transplan 2014; 29 (3): 490-496. doi: 10.1093/ndt/gft321

24. Cerbai E, Mugelli A. Lercanidipine and T-type calcium current. Eur Rev Med Pharmacol Sci 2018; 22 (12): 4025-4031. doi: 10.26355/eurrev_201806_15289

25. Sabbatini M, Leonardi A, Testa R et al. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35 (3):775-779. doi: 10.1161/01.HYP.35.3.775

26. Cominacini L, Fratta-Pasini A, Garbin U et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun 2003; 302 (4): 679-684. doi: 10.1016/S0006-291X(03)00158-X

27. Vasigar P, Batmanabane M. Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother 2013; 4 (4): 238-242. doi: 10.4103/0976-500X.119707

28. Fogari R, Mugellini A, Zoppi A et al. Differential effect of lercanidipine and nifedipine GTTS on plasma norepinephrine in chronic treatment of hypertension. Am J Hypertens 2003; 16 (7): 596-599. doi: 10.1016/S0895-7061(03)00901-4

29. Seravalle J, Brambilla J, Pizzalla DP et al. Differential effects of enalapril-felodipine versus enalapril-lercanidipine combination drug treatment on sympathetic nerve traffic and metabolic profile in obesity-related hypertension. J Am Soc Hypertens 2016; 10 (3): 244-251. doi: 10.1016/j.jash/2016.01.006

30. Tsiofis K, Tsiofis C, Dimitradis K et al. Differential effects of lercanidipine/enalapril versus amlodipine/enalapril and hydrochlorothiazide/enalapril on target organ damage and sympathetic activation in non-obese essential hypertensive subjects. Curr Med Res Opin 2016; 32 (supl 2): 35-41. doi: 10.1080/03007995.2016.1218839

31. Dalla-Vestra M, Pozza J, Mosca A et al. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive type 2 diabetic patients with microalbuminuria: DIAL study (diabetes, ipertensione, albuminuria, lercanidipine). Diabetes Nutr Metab 2004;17 (5):259-266

32. Robles NR, Ocon J, Gomez CF et al. Lercanidipine in patients with chronic renal failure. The ZAFRA study. Ren Fail 2005; 27 (1): 73-80. doi: 10.1081/JDI-42801

33. Robles NR, Romero B, de Vinuesa EG et al.. Treatment of proteinuria with lercanidipine associated with renin-angiotensin axis-blocking drugs. Ren Fail 2010; 32 (2): 192-197. doi: 10.3109/08860220903541135

34. Robles NR, Calvo C, Sobrino J et al. Lercanidipine valuable effect on urine protein losses: the RED LEVEL study. Curr Med Res Opin 2016; 32 (supl 2): 29-34. doi: 10.1080/03007995.2016.1218838

35. Кузьмин ОБ, Жежа ВВ, Ландарь ЛН. Нефропротективные свойства дигидропиридиновых блокаторов Са2+ каналов. Обзоры по клинической фармакологии и лекарственной терапии 2010; 8 (1): 6-12

36. Wu G, Xu M, Xu K, Hu Y. Benedipine protects kidney through inhibiting ROCK1 activity and reducing the epithelial-mesenchymal transdifferentiation in type 1 diabetic rats. J Diabetes Res 2013; 2013: 174526. doi: 10.1155/2013/174526

37. Kazama I, Baba A, Matsubara M et al. Benedipine suppresses in situ proliferation of leukocytes and slows the progression of renal fibrosis in rat kidneys with advanced chronic renal failure. Nephron Exp Nephrol 2014; 128 (1-2): 67-79. doi: 10.1159/000368080

38. Akizuki O, Inayoshi A, Kitayama T et al. Blockade of T-type voltage-dependent Ca2+ channels by benedipine, a dihydropyridine channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2008; 584 (1-3): 424-434. doi: 10.1016/j.ejphar.2008.02.001

39. Tsutamoto T, Tanaka T, Yamaji M et al. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension. Hypertens Res 2009; 32 (8): 670-674. doi: 10.1038/hr.2009.78

40. Abe M, Okada K, Maruyama N et al. Benedipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria. Hypertens Res 2011; 34 (2): 268-273. doi: 10.1038/hr.2010.221

41. Ohishi M, Takagi T, Ito N et al. Renal-protective effect of T- and L-type channel blockers in hypertensive patients: an amlodipine-to-benedipine changeover (ABC) study. Hypertens Res 2007; 30 (9): 797-806. doi: 10.1291/hypres.30.797

42. Abe M, Okada K, Maruyama T et al. Comparison of the antiproteinuric effects of the calcium channel blockers benedipine and amlodipine administered in combination with angiotensin receptor blockers to hypertensive patients with stage 3-5 chronic kidney disease. Hypertens Res 2009; 32 (4): 270-275.doi: 10.1038/hr.2009.11

43. Tani S, Takahashi A, Nagao K, Hirayama A. Effect of T/Ltype calcium channel blocker benedipine on albuminuria and plasma aldosterone concentration. A pilot study involving switching from L-type calcium channel blockers to benedipine. Int Heart J 2014; 55 (6): 519-525. doi: 10.1536/ihj.14-034

44. Takayama T, Yoda S, Yjima Y et al. Improvement of augmentation index and urinary albumin excretion with benedipine in hypertensive patients with chronic kidney disease. Int Heart J 2016; 57 (1): 53-60. doi: 10.1536/ihj.15-208

45. Hishikawa K, Takase O, Idei M, Fujito T. Comparison of antioxidant activity of cilnidipine and amlodipine. Kidney Int 2009; 76 (2) :230-231. doi: 10.1038/ki.2009.146

46. Hayashi M, Yamaji Y, Nakazato Y, Saruta T. The effect of calcium channel blockers on nuclear factor kappa B activation in the mesangial cells. Hypertens Res 2000; 23 (5): 521-525

47. Lei B, Nakano D, Fujisawa T et al. N-type calcium channel inhibition with cilnidipine elicits glomerular podocyte protection independent of sympathetic nerve inhibition. J Parmacol Sci 2012; 119 (4): 359-367. doi: 10.1254/jphs.12075FP

48. Mishima K, Maeshima A, Miya M et al. Involvement of N-type Ca (2+) channels in the fibrotic process of the kidney in the rats. Am J Physiol Renal Physiol 2013; 304 (6): F665-673. doi: 10.1152/ajprenal.00561.2012

49. Mori Y, Aritomi S, Niinuma K et al. Additive effects of cilnidipine, an L/N-type calcium channel blocker, and an angiotensin II receptor blocker on reducing cardiorenal damage in Otsuka Long-Evans Tokushima fatty rats with type 2 diabetes mellitus. Drug Des Devel Ther 2014; 8: 799-810. doi: 10.2147/DDDT.S47441

50. Uhrenholt TR, Nederquard O. Calcium channels involved in noradrenaline release from sympathetic neurons in rabbit carotid artery. Pharmacol Toxicol 2003; 92 (5): 226-233. doi: 10.1034/j.1600-0773.2003.920505

51. Toba H, Yoshida M, Tojo C et al. L/N-type calcium channel blocker cilnidipine ameliorates proteinuria and inhibits the renal renin-angiotensin-aldosterone system in desoxycorticosterone acetate-salt hypertensive rats. Hypertens Res 2011; 34 (4): 521-529. doi: 10.1038/hr.2010.279

52. Aritomi S, Wagatsuma H, Humata T et al. Expression of N-type calcium channels human adrenocortical cells and their contribution to corticosteroid synthesis. Hypertens Res 2011; 34 (2): 193-201. doi: 10.1038/hr.2010.191

53. Takahara A. Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 2009; 27 (2): 124-139. doi: 10.1111/j.1755-5922.2009.00079.x

54. Soeki T, Kitani M, Kusunose K et al. Renoprotective and antioxidant effects of cilnidipine in hypertensive patients. Hypertens Res 2012; 35 (11): 1058-1062. doi: 10.1038/hr.2012.96

55. Uchida S, Takahashi M, Sugawara M et al. Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (J-CIRCLE study). J Clin Hypertens (Greenwich) 2014; 16 (10): 746-753. doi: 10.1111/jch.12412

56. Singh VK, Mishra A, Gupta KK et al. Reduction of microalbuminuria in type 2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine. Indian J Nephrol 2015; 25 (6): 334-339. doi: 10.4103/0971-4065.151764

57. Konoshita T, Kaeriyama S, Urabe M et al. On the top of ARB N/L-type calcium channel blocker leads to less elevation of aldosterone. Biosci Rep 2016; 36 (5): e00381. doi: 10.1042/BSR20160129

58. Zhao PL, Wang XT, Zhang XM et al. Tubular and cellular localization of the cardiac L-type calcium channel in the rat kidney. Kidney Int 2002: 61 (4): 1398-1406. doi: 10.1046/j.1523-1755.2002.00267.x

59. Andreasen D, Jensen BL, Hansen PB et al. The alpha (1G)-subunits of voltage-dependent Ca (2+) channel is localized in rat distal nephron and collecting duct. Am J Physiol Renal Physiol 2000; 279 (6): F997-F1005

60. Xue C, Zhou C, Yang B et al. Comparison of efficacy and safety between benidipine and hydrochlorothiazide in fosinopriltreated hypertensive patients with chronic kidney disease: protocol for a randomized controlled trial. BMJ Open 2017; 7 (2): e013672. doi: 10.1136/bmjopen-2016-013672


Для цитирования:


Кузьмин О.Б., Жежа В.В., Белянин В.В. Дигидропиридиновые блокаторы кальциевых каналов для нефропротективной терапии гипертензивных больных с хронической болезнью почек. Нефрология. 2021;25(2):27-34. https://doi.org/10.36485/1561-6274-2021-25-2-27-34

For citation:


Kuzmin O.B., Zhezha V.V., Belyanin V.V. Dihydropyridine calcium channel blockers for the renoprotective therapy of hypertensive patients with chronic kidney disease. Nephrology (Saint-Petersburg). 2021;25(2):27-34. (In Russ.) https://doi.org/10.36485/1561-6274-2021-25-2-27-34

Просмотров: 249


ISSN 1561-6274 (Print)
ISSN 2541-9439 (Online)